Journal of Clinical Medicine · 2021 · 32 citations · 19 references
ATTR-CA patients with increasing NT-proBNP had an increased risk of EFS. Tafamidis stabilize NT-proBNP and cTnT-HS increasing, even if initial NT-proBNP levels were >3000 ng/L. Thus suggesting that all patients, irrespective of baseline NT-proBNP levels, may benefit from tafamidis.
19
Elliott M. Antman, Jean‐Pierre Bassand, Werner Klein et al. · Journal of the American College of Cardiology · 2000 · 4.8K citations
Joint European Society, Cardiovascular Epidemiology, Cardiovascular Disease +11
A new staging system for cardiac transthyretin amyloidosis
Julian D. Gillmore, Thibaud Damy, Marianna Fontana et al. · European Heart Journal · 2017 · 704 citations · Full text